Invectys, a Franco-American biopharmaceutical company of 25 people, developing innovative immunotherapy products for the treatment of cancers and immune system disorders,…
FRANÇOIS LESCURE, GENERAL MANAGER OF INVECTYS SAS, TO PARTICIPATE IN THE ABBVIE PARTNERING DAY IN PARIS, FRANCE ON OCTOBER 4TH, 2022 Paris, France, September…
9th International Conference on HLA-G July 4th – 5th 2022 Fondation Singer-Polignac, 43 Avenue Georges Mandel, 75116 Paris Invectys will be…
Invectys, MD Anderson and CTMC Announce Strategic Collaboration for CAR T Cell Therapy Development Houston, Texas, USA – June 16, 2022 – Invectys, Inc. (Invectys),…
Invectys, Inc. Appoints François Lescure as General Manager of its R&D Subsidiary, Invectys, SAS Houston, Texas, USA – April 11, 2022 (GLOBE NEWSWIRE) –…
Wayne A. Marasco, M.D., Ph.D. joins Invectys’ Scientific Advisory Board Houston, TX, USA, March 8, 2022 (GLOBE NEWSWIRE) — Invectys, Inc. of Houston, Texas,…
Invectys appoints Jian Cao, Ph.D., as Vice President, Pharmaceutical Development Houston, TX, USA, March 1st, 2022 (GLOBE NEWSWIRE) — Invectys, Inc. of Houston,…
Invectys to Provide 2022 Business Outlook at the H.C. Wainwright Bioconnect Virtual Conference Houston, Texas, USA – January 6th, 2022 (GLOBE NEWSWIRE) –…
